Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting

Documenti analoghi

• Prognostic value of the second revision of the international staging system (R2‐ISS) in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation
  di: Taku Kikuchi, et al.
  Pubblicazione: (2024)
• Cytomegalovirus Retinitis During Idecabtagene Vicleucel Therapy in Patients With Relapsed/Refractory Multiple Myeloma
  di: Taku Kikuchi, et al.
  Pubblicazione: (2025)
• Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab‐naïve relapsed multiple myeloma
  di: Danai Dima, et al.
  Pubblicazione: (2024)
• The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation
  di: Yutaka Shimazu, et al.
  Pubblicazione: (2024)
• Successful treatment of scleromyxedema with daratumumab, lenalidomide and dexamethasone in a patient with multiple myeloma
  di: Luca Bettolini, et al.
  Pubblicazione: (2024)